

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/022031-2023>

Tender

Process and Impact Evaluation

Genomics England

F02: Contract notice

Notice identifier: 2023/S 000-022031

Procurement identifier (OCID): ocds-h6vhtk-03eb5f

Published 28 July 2023, 3:15pm

Section I: Contracting authority

I.1) Name and addresses

Genomics England

One Canada Square

London

E14 5AB

Email

supplier.engagement@genomicsengland.co.uk

Telephone

+44 2078825030

Country

United Kingdom

Region code

UKI - London

Internet address(es)

Main address

www.genomicsengland.co.uk

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at

<https://genomicsengland.bravosolution.co.uk>

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

<https://genomicsengland.bravosolution.co.uk>

Tenders or requests to participate must be submitted to the above-mentioned address

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Process and Impact Evaluation

Reference number

GEL-SR-534-22

II.1.2) Main CPV code

- 73210000 - Research consultancy services

II.1.3) Type of contract

Services

II.1.4) Short description

Genomics England's Generation Study aims to explore the benefits, challenges, and practicalities of offering whole genome sequencing to newborns, to accelerate diagnosis and access to treatment for rare genetic conditions. The programme funding was confirmed on 13 December 2022 with £105 million of funding to support it. Should it prove beneficial for participants and the wider health service, the study could pave the way for what would be the world's first national newborn screening programme to incorporate whole genome sequencing.

The outcome for this project is for Genomics England to work in partnership with an organisation or group of organisations with the specific expertise to deliver the Generation Study evaluation. The Generation Study will:

1. evaluate the scientific and clinical utility and validity, operational feasibility, and impact on the NHS of using Whole Genome Sequencing to screen for a large number of childhood-onset rare genetic conditions and provide ongoing patient support
2. understand how, with consent, newborns' genomic and health data could be used for research to enable new diagnostic discoveries and treatments to be developed
3. explore the potential risks, benefits, and broader implications of storing an individual's genome over their lifetime (e.g., potential for preventative steps, personalised risk-based screening in later life etc.)

Please note that this tender seeks a partner to evaluate the first of these three aims only.

II.1.6) Information about lots

This contract is divided into lots: No

II.2) Description

II.2.2) Additional CPV code(s)

- 73000000 - Research and development services and related consultancy services

II.2.3) Place of performance

NUTS codes

- UKI - London

II.2.4) Description of the procurement

Two key components for which we require specific expertise in implementation science, behavioural science, health informatics and health economics are:

- Process Evaluation - will address research questions focusing specifically on whether the programme is acceptable and feasible. It will assess study delivery and processes to inform decision making for a possible future clinical service.

- Impact Evaluation - will address possible benefits and harms to:

- o Stakeholders – including participants, Health Care professionals, and the public

- o The System – including impact on existing newborn screening programmes and the impact on WGS for other patients as well as understanding comparative costs on the health care system.

- o Experiences and Attitudes – including participants, the public and 3rd sector organisations.

Genomics England will act as sponsor for the Generation Study and associated evaluation work. Genomics England is ultimately accountable for the research of which this evaluation forms part. The successful Tenderer will be responsible for design and delivery of all research related activities pursuant to the bid, including but not limited to the delivery of documents for the HRA and any other relevant regulatory bodies (where necessary).

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

18

This contract is subject to renewal

Yes

Description of renewals

An extension option of up to 12 months will be available for this contract

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2.14) Additional information

Interested parties should register with Genomics England's e-tendering portal <https://genomicsengland.bravosolution.co.uk> and search for project_857 to access all relevant documentation.

Section III. Legal, economic, financial and technical information

III.1) Conditions for participation

III.1.2) Economic and financial standing

Selection criteria as stated in the procurement documents

III.1.3) Technical and professional ability

Selection criteria as stated in the procurement documents

III.2) Conditions related to the contract

III.2.3) Information about staff responsible for the performance of the contract

Obligation to indicate the names and professional qualifications of the staff assigned to performing the contract

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: No

IV.2) Administrative information

IV.2.2) Time limit for receipt of tenders or requests to participate

Date

8 September 2023

Local time

12:00pm

IV.2.4) Languages in which tenders or requests to participate may be submitted

English

IV.2.6) Minimum time frame during which the tenderer must maintain the tender

Tender must be valid until: 1 November 2023

IV.2.7) Conditions for opening of tenders

Date

8 September 2023

Local time

12:00pm

Section VI. Complementary information

VI.1) Information about recurrence

This is a recurrent procurement: No

VI.2) Information about electronic workflows

Electronic ordering will be used

Electronic invoicing will be accepted

Electronic payment will be used

VI.3) Additional information

Interested parties should register with Genomics England's e-tendering portal <https://genomicsengland.bravosolution.co.uk> and search for project_857 to access all relevant documentation.

VI.4) Procedures for review

VI.4.1) Review body

Public Procurement Review Service

London

Country

United Kingdom